🎥 Marcello Moccia comments on the association between neurofilament and invisible symptoms of #MultipleSclerosis, including cognitive dysfunction, depression, and fatigue:

👉 buff.ly/eW8A7YG 👈

#MS #MultScler #Neuroscience #Neurology #EAN2025 #MedSky

In an interview from #EAN2025, Celia Oreja-Guevara discusses the importance of early detection of silent progression in patients with #MS.

Click here to watch:
👉 buff.ly/YhEAYwv 👈

#MultScler #MultipleSclerosis #Neurology #MedSky

Watch our interview with Marcello Moccia to hear about a study comparing different age-derived cut-offs for plasma neurofilament light chain in #MultipleSclerosis.

Click here:
👉 buff.ly/yaa0Q9L

#MS #MultScler #Neuroscience #Neurology #EAN2025

What is the impact of the new McDonald diagnostic criteria for #MultipleSclerosis? 🧠

Marcello Moccia discussed this in a recent interview:

🎥 buff.ly/9DcoI2r

#MS #MultScler #Neuroscience #Neurology #EAN2025 #MedSky

Want to hear the details of a study investigating soluble factors that contribute to broad rim lesion formation in #MultipleSclerosis?

Then make sure to check out our interview with Joost Smolders from #EAN2025:

🎥 buff.ly/P7pXCa9

#CTSM #MS #MultScler #Neurology #MedSky

Want to find out about the recent revision of the McDonald criteria for the diagnosis of #MultipleSclerosis?🧠

Click here to watch our insightful interview with Marcello Moccia:

👉 buff.ly/1E9VzZJ

#MS #MultScler #Neuroscience #Neurology #EAN2025 @ean.org #MedSky

The EnvIMS study was a multinational case-control study investigating childhood infections and their impact on #MultipleSclerosis onset in adults.

Caterina Ferri shares the findings in an interview from #EAN2025:

🎥 buff.ly/RRgMxfp

#MS #MultScler #CTSM #Neurology #MedSky

In an interview from #EAN2025, Celia Oreja-Guevara comments on the inclusion of the central vein sign in the McDonald diagnostic criteria for #MultipleSclerosis to allow for its differentiation from similar diseases:

👉 buff.ly/yR8xfQv

#MultScler #Neurology #Neuroscience #MedSky @ean.org

Want to hear as Celia Oreja-Guevara shares her highlights in #MultipleSclerosis from #EAN2025? 🧠

Make sure to check out our interview with her by clicking here:

👉 buff.ly/4YnGgfV 👈

#MS #MultScler #MedSky #Neurology @ean.org

As it's #WorldMSDay, why not listen to our podcast with leading experts who provide insight into the recent revision of the McDonald diagnostic criteria for #MultipleSclerosis?🧠

Check it out here:
🎧 buff.ly/5R4rqcU

#MS #MultScler #Neurology #MSAwareness #MedSky

#AANAM | Enric Monreal discusses the role of biomarkers in transitioning from evidence-based medicine to personalized medicine in #MultipleSclerosis:

🎥 buff.ly/cCDoeEs

#MedSky #MS #MultScler #Neurology #Neuroscience

#MSWeek | Enric Monreal presents findings of a study investigating the predictive value of the combination of CSF and serum biomarkers at disease onset in #MultipleSclerosis. 🧠🩸

Watch here:
🎥 buff.ly/UWJgWR8

#MS #MultScler #Neurology #AANAM

Metabolic and lipid alterations in multiple sclerosis linked to disease severity - Rezvan Noroozi, Hui-Hsin Tsai, Ketian Yu, Paola Bronson, Karunakar Samuel, Kien Trinh, Ru Wei, Ellen Tsai, Farren BS ... Background: The circulating metabolome incorporates multiple levels of biological interactions and is an emerging field for biomarker discovery. However, few st...

Metabolic and lipid alterations in multiple sclerosis linked to disease severity #MultScler #MassSpec journals.sagepub.com/doi/10.1177/...

At the European CAR T-cell meeting, we spoke with Johanna Richter to hear about the preliminary data from a single-center experience with CD19-directed CAR-T in patients with #MultipleSclerosis.

Watch here:
👉 buff.ly/Xyuvgwu

#MS #MultScler #CART25 #Neurology

There is a need to enhance the use of advanced MRI in MS diagnosis and monitoring.🧠

Hear more about this in our interview with Dr Serena Borrelli:

🎥 https://buff.ly/3CD7dlY

#MS #MultScler #MultipleSclerosis #EAN2024 #Neuroscience

🎥 Dr Serena Borrelli discusses a proposed approach for simplifying the assessment of central vein sign positivity in clinical practice.

Click here to watch:
👉 https://buff.ly/40nXHuQ 👈

#MS #MultScler #MultipleSclerosis #EAN2024 #Neuroscience

#ECTRIMS2024 | Emilio Portaccio outlines the two ways disability accrual occurs in #MultipleSclerosis – relapse-associated worsening (RAW) & progression independent from relapse activity (PIRA).

Click here:
👉 https://buff.ly/4gZeUl3

#MultScler #MS #Neurology #Neuroscience

Have you listened to our newest podcast yet?🤔🎧

Don't miss out on this fantastic episode if you want to gain insight into the latest updates to the McDonald diagnostic criteria for #MultipleSclerosis.🧠

Listen here:
👉 https://buff.ly/41c1qOe 👈

#MS #MultScler

The central vein sign (CVS) is a central linear hypointensity within lesions on T2*-weighted imaging.

Celia Oreja-Guevara discusses its clinical value in the diagnosis of #MultipleSclerosis:

👉 https://buff.ly/4iAq15x 👈

#MS #MultScler #Neuroscience #Neurology

What are the similarities between chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and #MultipleSclerosis?🤔

Watch our interview with Alicja Kalinowska to find out:
👉 https://buff.ly/49HS5jb

#MS #MultScler

Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS - VJNeurology Maya Zeineddine, PharmD, Lebanese American University, Byblos, Lebanon, discusses the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in...

Earlier this year, we interviewed Maya Zeineddine to hear about the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in #MultipleSclerosis.

Watch here:
👉 https://buff.ly/3ZAA42V

#MS #MultScler #ECTRIMS2024 #Neuroscience

Investigating CAR T-cell therapy in the treatment of MS - VJNeurology Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the potential use of chimeric antigen receptor (CAR) T-cell therapy to...

#CARTCell therapy has revolutionized the treatment of hematological malignancies and is now being considered as a potential treatment for neurological conditions, including #MultipleSclerosis!

Learn more from Krish Patel here:
👉https://buff.ly/3Z7S7MG

#ECTRIMS2024 #MS #MultScler

Investigating evobrutinib and other BTK inhibitors for the treatment of MS - VJNeurology Anneke Van der Walt, PhD, Monash University, Melbourne, Australia, discusses the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor,...

It was a pleasure to interview Anneke Van der Walt, who provided insight into evobrutinib and other BTK inhibitors for the treatment of #MultipleSclerosis.

Click here to watch:
👉 https://buff.ly/3Z8JMbw

#ECTRIMS2024 #MultScler #MS #Neuroscience #Neurology

In an interview from #ECTRIMS2024, Helen Tremlett introduces the concept of a prodromal phase in #MultipleSclerosis and comments on how it has been neglected.

Watch it here:
👉 https://buff.ly/3B1PiVt

#MultScler #MS #Neuroscience #Neurology

Our new podcast is live! 🎧

Hear about the latest updates to the McDonald diagnostic criteria for #MultipleSclerosis from leading experts in the field. 🧠

Click here to listen:
👉 https://buff.ly/41c1qOe 👈

#MS #MultScler #Neurology #Neuroscience

🎥 Lilyana Amezcua, MD, FAAN, discusses the Phase IV CHIMES trial, evaluating ocrelizumab’s efficacy in Black/African American and Hispanic/Latino individuals with relapsing #MultipleSclerosis:

👉 https://buff.ly/4fAeFMS 👈

#MS #MultScler #AANAM #CTSM #TrialUpdate #Neuroscience #Neurology

Want to hear about the current state of clinical evidence regarding the use of stem cell therapies in patients with #MultipleSclerosis?

Watch our interview with Andrew Wolf, MD:
👉 https://buff.ly/48ZC7R9 👈

#MS #MultScler #AANAM #Neurology #Neuroscience